P. Troke

发表

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus

C. Spencer, P. Klenerman, P. Simmonds, 2019, eLife.

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

P. Troke, C. Craig, M. Westby, 2011, Antimicrobial Agents and Chemotherapy.

A Conserved α-Helical Motif Mediates the Binding of Diverse Nuclear Proteins to the SRC1 Interaction Domain of CBP*

P. Troke, D. Heery, Colm M. Ryan, 2004, Journal of Biological Chemistry.

MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.

E. Kalkhoven, P. Troke, H. Collins, 2006, The Journal of biological chemistry.

MOZ fusion proteins in acute myeloid leukaemia.

P. Troke, H. Collins, D. Heery, 2006, Biochemical Society symposium.

DNA-binding and regulatory properties of the transcription factor and putative tumor suppressor p150(Sal2).

H. Gu, Dawei Li, P. Troke, 2011, Biochimica et biophysica acta.

Mechanism of action of nikkomycin and the peptide transport system of Candida albicans.

K. Gull, P. Troke, P. McCarthy, 1985, Journal of general microbiology.

Hepatitis C Virus Therapy PF-05095808, a Novel Biological Agent for Characterization of the Activity of In Vitro

Frances Burden, P. Troke, J. F. Wright, 2012 .

In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy

Frances Burden, K. Brady, P. Troke, 2011, Antimicrobial Agents and Chemotherapy.

THE MECHANISM OF SALT TOLERANCE IN HALOPHYTES

P. Troke, T. Flowers, A. Yeo, 1977 .

968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS

P. Troke, M. Perros, C. Craig, 2009 .

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

P. Troke, J. Hammond, F. Wagner, 2011, Hepatology.

HIV-1 proteinase is required for synthesis of pro-viral DNA.

A. Dalgleish, P. Troke, C. Baboonian, 1991, Biochemical and biophysical research communications.

Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

John A. Tallarico, T. Bouwmeester, M. Schirle, 2009, Journal of Virology.

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

Joshua B. Singer, E. Barnes, J. Benselin, 2021, Journal of viral hepatitis.

Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs

E. Barnes, J. Benselin, J. McLauchlan, 2020, medRxiv.

MOZ-TIF2 Inhibits Transcription by Nuclear Receptors and p53 by Impairment of CBP Function

S. Minucci, P. Pelicci, C. Bellodi, 2005, Molecular and Cellular Biology.

The leukaemogenic fusion protein MOZ-TIF2 inhibits nuclear receptor-mediated transcription and mislocalises CBP

P. Troke, 2003 .

Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset

M. Manns, W. Irving, G. Foster, 2016 .

Fluconazole resistance in Candida glabrata

P. Troke, E. Johnson, D. Warnock, 1993, Antimicrobial Agents and Chemotherapy.